Preclinical Evidence for Mifepristone in Breast Cancer: A Systematic Review and Meta-analysis of Animal Studies.
Mifepristone (MIF), an antagonist of the progesterone receptor (PR) and glucocorticoid receptor (GR), has shown antitumor activity in experimental breast cancer, but the consistency and certainty of the preclinical evidence remain unclear. We systematically searched PubMed, Embase, Web of Science, and the China Nationa...